WallStreetZenWallStreetZen

NASDAQ: SLN
Silence Therapeutics PLC Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SLN past revenue growth

How has SLN's revenue growth performed historically?
Company
52.33%
Industry
148.4%
Market
16.96%
SLN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SLN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SLN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SLN earnings and revenue history

Current Revenue
$32.1M
Current Earnings
-$54.8M
Current Profit Margin
-170.5%

SLN Return on Equity

Current Company
-262.6%
Current Industry
-63.5%
Current Market
188%
SLN's Return on Equity (-262.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SLN announces earnings.

SLN Return on Assets

Current Company
-47%
Current Industry
2.9%
SLN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SLN Return on Capital Employed

Current Company
-63.32%
Current Industry
19.5%
SLN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SLN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SLN$32.12M-$60.37M-$54.77M+216.26%N/A
BCRX$331.41M-$116.34M-$226.54M+74.21%N/A
SAVA$0.00-$95.69M-$97.22MN/AN/A
IMTX$58.69M-$97.57M-$105.43M+69.15%N/A
IMNM$14.02M-$106.08M-$106.81MN/AN/A
View Top Biotech Stocks

SLN earnings dates

Next earnings date
May 14, 2024

Silence Therapeutics Earnings & Revenue FAQ

What were SLN's earnings last quarter?

On Invalid Date, Silence Therapeutics (NASDAQ: SLN) reported Q4 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Silence Therapeutics earnings for the quarter were -$18.24 million. In the same quarter last year, Silence Therapeutics's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Silence Therapeutics stock.

What was SLN's earnings growth in the past year?

As of Q2 2024, Silence Therapeutics's earnings has grown year over year. Silence Therapeutics's earnings in the past year totalled -$54.77 million.

What is SLN's earnings date?

Silence Therapeutics's earnings date is Invalid Date. Add SLN to your watchlist to be reminded of SLN's next earnings announcement.

What was SLN's revenue last quarter?

On Invalid Date, Silence Therapeutics (NASDAQ: SLN) reported Q4 2023 revenue of $2.66 million up 53.72% year over year. In the same quarter last year, Silence Therapeutics's revenue was $5.74 million.

What was SLN's revenue growth in the past year?

As of Q2 2024, Silence Therapeutics's revenue has grown 52.33% year over year. This is 96.07 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Silence Therapeutics's revenue in the past year totalled $32.12 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.